Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non-Current Liabilities: 2020-2025

Historic Other Non-Current Liabilities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $43.9 million.

  • Insight Molecular Diagnostics' Other Non-Current Liabilities fell 9.78% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year decrease of 9.78%. This contributed to the annual value of $37.7 million for FY2024, which is 5.49% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Other Non-Current Liabilities stood at $43.9 million for Q3 2025, which was up 7.36% from $40.9 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Other Non-Current Liabilities ranged from a high of $76.7 million in Q4 2021 and a low of $8.2 million during Q1 2021.
  • Over the past 3 years, Insight Molecular Diagnostics' median Other Non-Current Liabilities value was $39.9 million (recorded in 2023), while the average stood at $36.7 million.
  • In the last 5 years, Insight Molecular Diagnostics' Other Non-Current Liabilities spiked by 976.98% in 2021 and then crashed by 84.55% in 2023.
  • Insight Molecular Diagnostics' Other Non-Current Liabilities (Quarterly) stood at $76.7 million in 2021, then slumped by 40.45% to $45.7 million in 2022, then fell by 12.62% to $39.9 million in 2023, then declined by 5.49% to $37.7 million in 2024, then decreased by 9.78% to $43.9 million in 2025.
  • Its Other Non-Current Liabilities was $43.9 million in Q3 2025, compared to $40.9 million in Q2 2025 and $38.4 million in Q1 2025.